RT Journal Article
SR Electronic
T1 Monocyte-chemoattractant protein-1 Levels in Human Atherosclerosis Associate with Plaque Vulnerability
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.04.20187955
DO 10.1101/2020.09.04.20187955
A1 Georgakis, Marios K.
A1 van der Laan, Sander W.
A1 Asare, Yaw
A1 Mekke, Joost M.
A1 Haitjema, Saskia
A1 Schoneveld, Arjan H.
A1 de Kleijn, Dominique P.V.
A1 de Borst, Gert J.
A1 Pasterkamp, Gerard
A1 Dichgans, Martin
YR 2020
UL http://medrxiv.org/content/early/2020/09/05/2020.09.04.20187955.abstract
AB Monocyte chemoattractant protein-1 (MCP-1) recruits monocytes to the atherosclerotic plaque. While experimental,1–6 genetic,7 and observational8,9 data support a key role of MCP-1 in atherosclerosis, the translational potential of targeting MCP-1 signaling for lowering vascular risk is limited by the lack of data on plaque MCP-1 activity in human atherosclerosis. Here, we measured MCP-1 levels in human plaque samples from 1,199 patients undergoing carotid endarterectomy and explored associations with histopathological, molecular, and clinical features of plaque vulnerability. MCP-1 plaque levels were associated with histopathological hallmarks of plaque vulnerability (large lipid core, low collagen, high macrophage burden, low smooth muscle cell burden, intraplaque hemorrhage) as well as molecular markers of plaque inflammation and matrix turnover, clinical plaque instability, and periprocedural stroke during plaque removal. Collectively, our findings highlight a role of MCP-1 in human plaque vulnerability and suggest that interfering with MCP-1 signaling in patients with established atherosclerosis could lower vascular risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Union's Horizon 2020 research and innovation programme (666881); SVDs@target (to MD; 667375); CoSTREAM (to MD); the DFG as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy; ID 390857198) and the CRC 1123 (B3; to MD); the Corona Foundation (to MD); the Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain; to MD); the e:Med program (e:AtheroSysMed; to MD) and the FP7/2007-2103 European Union project CVgenes@target (grant agreement number Health-F2-2013-601456; to MD). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol conforms to the Declaration of Helsinki and was approved by the ethics committee on research on humans of the University Medical Center Utrecht. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets from Ahero-Express analyzed during the current study are available upon request to the corresponding author and application to Athero-Express through a Template Material/Data Transfer Agreement due to consent restriction. The code used for the current study is available through GitHub under the following link: https://github.com/swvanderlaan/2020_georgakis_vanderlaan_MCP1 https://github.com/swvanderlaan/2020_georgakis_vanderlaan_MCP1